



09-507968

CJC

PTO/SB/17 (12-04)

Approved for use through 7/31/2006. OMB 0651-0032

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no person are required to respond to a collection of information unless it displays a valid OMB control number.

<b>Effective on 12/08/2004.</b> Fees pursuant to the Consolidated Appropriations Act, 2005 (H.R. 4818). <b>FEE TRANSMITTAL</b> <b>For FY 2005</b>		<b>Complete if Known</b>	
		Application Number	Patent#: 6,812,327
		Filing Date	Issued: November 2, 2004
		First Named Inventor	Guo-Liang Yu
		Examiner Name	B. E. Bunner
<input type="checkbox"/> Applicant claims small entity status. See 37 CFR 1.27	Art Unit	1647	<b>Certificate</b>
<b>TOTAL AMOUNT OF PAYMENT</b>	<b>(\$)</b> 0.00	Attorney Docket No.	

DEC 27 2004

**METHOD OF PAYMENT** (check all that apply)

☐ Check ☐ Credit Card ☐ Money Order ☐ None ☐ Other (please identify): **of Correction**

☒ Deposit Account      Deposit Account Number: **08-3425**      Deposit Account Name: **Human Genome Sciences, Inc.**

For the above-identified deposit account, the Director is hereby authorized to: (check all that apply)

☐ Charge fee(s) indicated below      ☐ Charge fee(s) indicated below, except for the filing fee

☐ Charge any additional fee(s) or any underpayment of fee(s) under 37 CFR 1.16 and 1.17      ☒ Credit any overpayments

**FEE CALCULATION**

**1. BASIC FILING, SEARCH, AND EXAMINATION FEES**

Application Type	Fee (\$)	FILING FEES	SEARCH FEES	EXAMINATION FEES	Fees Paid (\$)
		Small Entity Fee (\$)	Small Entity Fee (\$)	Small Entity Fee (\$)	
Utility	300	150	500	200	100
Design	200	100	100	130	65
Plant	200	100	300	160	80
Reissue	300	150	500	600	300
Provisional	200	100	0	0	0

**2. EXCESS CLAIM FEES**

Fee Description	Fee (\$)	Small Entity Fee (\$)
Each claim over 20 or, for Reissues, each claim over 20 and more than in the original patent	50	25
Each independent claim over 3 or, for Reissues, each independent claim more than in the original patent	200	100
Multiple dependent claims	360	180

**Total Claims** 222 - 392 = **Extra Claims** x **Fee (\$)** = **Fee Paid (\$)**

**Indep. Claims** 17 - 18 = **Extra Claims** x **Fee (\$)** = **Fee Paid (\$)**

**3. APPLICATION SIZE FEE**

If the specification and drawings exceed 100 sheets of paper, the application size fee due is \$250 (\$125 for small entity) for each additional 50 sheets or fraction thereof. See 35 U.S.C. 41(a)(1)(G) and 37 CFR 1.16(s).

Total Sheets	Extra Sheets	Number of each additional 50 or fraction thereof	Fee (\$)	Fee Paid (\$)
- 100 =	/50	(round up to a whole number) x	=	

**4. OTHER FEE(S)**

Non-English Specification, \$130 fee (no small entity discount)

Other:

<b>SUBMITTED BY</b>			
Signature	<i>Michele Shannon</i>	Registration No. (Attorney/Agent)	47,075
Name (Print/Type)	Michele Shannon	Telephone	(301) 354-3930
		Date	December 20, 2004

DEC 28 2004



THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Letters Patent of: Yu, et al.

Attorney Docket No.: PF343P3

Patent No.: 6,812,327 B1

Issued: November 2, 2004

Title: Neutrokin-Alpha Polypeptides

**REQUEST FOR CERTIFICATE OF CORRECTION  
PURSUANT TO 37 C.F.R. § 1.322**

**Attn: Certificate of Correction Branch**

Commissioner for Patents

P.O. Box 1450

Alexandria, VA 22313-1450

Sir:

Upon reviewing the above-identified patent, Patentees noted the following mistakes that should be corrected:

**In the Specification:**

On the cover page, line 4 under "Related U.S. Application Data," delete "Pat. No. 6,689,579, and" and insert -- Pat. No. 6,689,579, which is -- ;

On the cover page, under FOREIGN PATENT DOCUMENTS, insert:

-- WO 98/18921 05/1998

WO 00/50597 08/2000 --

On the cover page, under OTHER PUBLICATIONS, insert:

-- CHEEMA et al., Elevated Serum B Lymphocyte Stimulator Levels in Patients with Systemic Immune-Based Rheumatic Diseases, *Arthritis and Rheumatism* (2001) 44:1313-1319. --

On the cover page, in the Abstract, delete the third sentence and replace it with the following:

-- Neutrokin-alpha and/or Neutrokin-alphaSV polypeptides are also provided as are vectors, host cells and recombinant methods for producing the same. --

DEC 28 2004

**In the Claims:**

In Claim 5, delete "claim 1" and insert -- claim 4 -- ;

In Claim 179, delete "proliferation" and insert -- differentiation -- ;

In Claim 216, delete "claim 165" and insert -- claim 166 -- .

Support for the correction to the priority information can be found in the first paragraph of the application as amended on May 3, 2002.

Support for the missing references in the Foreign Patent Documents section can be found in PTO Form 892 attached to the Office Action dated January 31, 2003 (see references B3 and B4). Support for the missing Cheema *et al.* reference in the Other Publications section can be found in PTO Form SB/08 attached to the Advisory Action mailed July 7, 2003 (see reference B5). Support for the corrections to the claims can be found in the Clean Version of the Entire Set of Pending Claims Under 37 C.F.R. § 1.121(c)(3) filed by Applicants on July 16, 2003, in which claims 32, 314, 410, 26, and 290 correspond to claims 5, 179, 216, 4, and 166 in the 6,812,327 patent, respectively. Support for the corrections to the abstract may be found in the Abstract as originally filed.

The above mistakes were not in the application as filed or amended by Patentees, and thus appear to be the fault of the Patent and Trademark Office. Accordingly, it is hereby requested that a Certificate of Correction under 37 C.F.R. § 1.322 be issued for the above-identified patent. Pursuant to 35 U.S.C. § 254 and 37 C.F.R. § 1.322, no fee is required.

Submitted herewith is a proposed Certificate of Correction (Form PTO/SB/44). Patentees respectfully request the issuance of the Certificate of Correction.

Respectfully submitted,



Michele Shannon      Reg. No. 47,075  
Senior Patent Agent

**Human Genome Sciences, Inc.**  
14200 Shady Grove Road  
Rockville, MD 20850  
Telephone: 301-354-3930

Dated: December 20, 2004

KKH/MS/mr

## UNITED STATES PATENT AND TRADEMARK OFFICE CERTIFICATE OF CORRECTION

PATENT NO. : 6,812,327 B1  
DATED : November 2, 2004  
INVENTOR(S) : Yu, et al.

It is certified that error appears in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

**In the Specification:**

On the cover page, line 4 under "Related U.S. Application Data," delete "Pat. No. 6,689,579, and" and insert -- Pat. No. 6,689,579, which is -- ;

On the cover page, under FOREIGN PATENT DOCUMENTS, insert:

-- WO 98/18921 05/1998  
WO 00/50597 08/2000 --

On the cover page, under OTHER PUBLICATIONS, insert:

-- CHEEMA et al., Elevated Serum B Lymphocyte Stimulator Levels in Patients with Systemic Immune-Based Rheumatic Diseases, *Arthritis and Rheumatism* (2001) 44:1313-1319. --

On the cover page, in the Abstract, delete the third sentence and replace it with the following:

-- Neutrokine-alpha and/or Neutrokine-alphaSV polypeptides are also provided as are vectors, host cells and recombinant methods for producing the same. --

**In the Claims:**

In Claim 5, delete "claim 1" and insert -- claim 4 -- ;

In Claim 179, delete "proliferation" and insert -- differentiation -- ;

In Claim 216, delete "claim 165" and insert -- claim 166 -- .

MAILING ADDRESS OF SENDER:  
Michele Shannon  
HUMAN GENOME SCIENCES, INC.  
14200 Shady Grove Road  
Rockville, Maryland 20850

PATENT NO.: 6,812,327 B1

No. of additional copies: 0

DEC 28 2004